China Pharma (NYSE:CPHI) Shares Down 1% – What’s Next?

China Pharma Holdings, Inc. (NYSE:CPHI)’s share price traded down 1% during trading on Tuesday . The stock traded as low as $0.5204 and last traded at $0.55. 12,815 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 60,485 shares. The stock had previously closed at $0.5554.

China Pharma Stock Performance

The company has a 50-day moving average of $1.00 and a 200-day moving average of $1.44. The company has a market cap of $2.76 million, a PE ratio of -0.96 and a beta of 1.17. The company has a quick ratio of 0.26, a current ratio of 0.79 and a debt-to-equity ratio of 0.22.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC boosted its position in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 as of its most recent SEC filing.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.